Lise Ventzel
YOU?
Author Swipe
Circulating tumour DNA (ctDNA) as a predictor of progression-free and overall survival in non-resectable pancreatic cancer: a systematic review and meta-analysis Open
Background: This systematic review and meta-analysis synthesised current evidence on circulating tumour DNA (ctDNA) for predicting clinical outcomes in patients with non-resectable pancreatic ductal adenocarcinoma (PDAC). Methods: PubMed, …
Survivor-driven development of a PROM for use in routine colorectal cancer care Open
Background and purpose: Despite the availability of patient reported outcome (PRO) measures (PROMs) for assessing survivorship care needs, their successful implementation remains limited. This study aimed to improve the likelihood of imple…
Chronic chemotherapy-induced peripheral neuropathy and pain following paclitaxel versus docetaxel in breast cancer survivors: A cross-sectional study Open
Chemotherapy-induced peripheral neuropathy (CIPN) is a concerning late effect of taxane treatment. This study aimed to explore and compare long-term symptoms and consequences of CIPN after docetaxel and paclitaxel treatment. Patients with …
Chemotherapy-induced peripheral neuropathy among breast cancer survivors Open
This review investigates that effective cancer treatment enhances the number of survivors in Denmark, but late complications like chemotherapy-induced peripheral neuropathy (CIPN) are a challenge. CIPN affects sensory nerves and can persis…
Study protocol: fish oil supplement in prevention of oxaliplatin-induced peripheral neuropathy in adjuvant colorectal cancer patients – a randomized controlled trial. (OxaNeuro) Open
Background Oxaliplatin-induced peripheral neuropathy (OIPN) in general and painful OIPN in particular is a debilitating late effect that severely affects cancer survivors’ quality of life and causes premature cessation of potentially lifes…
View article: A randomized phase II study of full dose gemcitabine versus reduced dose gemcitabine and nab-paclitaxel in vulnerable patients with non-resectable pancreatic cancer (DPCG-01)
A randomized phase II study of full dose gemcitabine versus reduced dose gemcitabine and nab-paclitaxel in vulnerable patients with non-resectable pancreatic cancer (DPCG-01) Open
Background According to current evidence, the best treatment for fit patients with non-resectable pancreatic cancer (PC) is combination chemotherapy, whereas frail patients are recommended gemcitabine (Gem) monotherapy. Randomized controll…
Management of treatment‐related sequelae following colorectal cancer Open
Aim Colorectal cancer survivors are one of the most rapidly growing groups of patients living with and beyond cancer. In a national multidisciplinary setting, we have examined the extent of late treatment‐related sequelae in colorectal can…
Assessing pain after cancer treatment Open
Objectives Chronic pain is common following cancer treatment. This is a brief discussion of pain assessment after cancer treatment. Methods Summary of a lecure for the SASP (Scandinavian Journal of Pain) annual meeting 2022. Results Assess…
Neuropathy and pain after breast cancer treatment: a prospective observational study Open
Objectives Neurological complications including pain are common after treatment for breast cancer. This prospective study investigated the symptoms, intensity and interference of chemotherapy-induced peripheral neuro-pathy. (CIPN) in the f…
View article: Axonal Excitability Does Not Differ between Painful and Painless Diabetic or Chemotherapy‐Induced Distal Symmetrical Polyneuropathy in a Multicenter Observational Study
Axonal Excitability Does Not Differ between Painful and Painless Diabetic or Chemotherapy‐Induced Distal Symmetrical Polyneuropathy in a Multicenter Observational Study Open
Objective Axonal excitability reflects ion channel function, and it is proposed that this may be a biomarker in painful (vs painless) polyneuropathy. Our objective was to investigate the relationship between axonal excitability parameters …
Association of sensory phenotype with quality of life, functionality, and emotional well-being in patients suffering from neuropathic pain Open
Neuropathic pain highly affects quality of life, well-being, and function. It has recently been shown based on cluster analysis studies that most patients with neuropathic pain may be categorized into 1 of 3 sensory phenotypes: sensory los…
Oxaliplatin‐ and docetaxel‐induced polyneuropathy: clinical and neurophysiological characteristics Open
The aim of this study was to evaluate the presence and characterization of chemotherapy‐induced neuropathy (CIPN) and neuropathic pain 5 years after adjuvant chemotherapy with docetaxel or oxaliplatin. Patients from an ongoing prospective …
Long‐term symptoms of polyneuropathy in breast and colorectal cancer patients treated with and without adjuvant chemotherapy Open
Background The aim of this study was to assess chemotherapy‐induced polyneuropathy (CIPN) 5 years after adjuvant chemotherapy in patients with breast and colorectal cancer. The association of CIPN with quality of life, anxiety, and depress…
Cold aggravates abnormal excitability of motor axons in oxaliplatin‐treated patients Open
Introduction Cold allodynia is often seen in the acute phase of oxaliplatin treatment, but the underlying pathophysiology remains unclear. Methods Patients scheduled for adjuvant oxaliplatin for colorectal cancer were examined with quantit…
Neurophysiologic assessment of sensory denervation in chemotherapy induced polyneuropathy Open
In patients with suspicion of chemotherapy induced polyneuropathy (CI-PNP), demonstration of large- and small fiber sensory polyneuropathy (LFN and SFN, respectively) is essential to decide alteration or cessation of chemotherapy. Thirty p…
Chronic Pain and Neuropathy Following Adjuvant Chemotherapy Open
Both oxaliplatin-induced and docetaxel-induced polyneuropathies represent a significant problem that affects the daily life of the patients. Our results, defining the somatosensory phenotype, can improve the understanding of the pathophysi…